Laminar, Pharmaceuticals

Laminar Pharmaceuticals S.A. receives recommendation from the Independent Data Monitoring Committee to advance to the next stage of CLINGLIO, the phase 2b/ 3 Clinical Trial of LAM561 in combination with RT and TMZ for adults with newly diagnosed glioblasto

Published on 08/07/2025 at 18:00 | prnewswire.co.uk

Laminar Pharmaceuticals, S.A. Spain

View original content:https://www.prnewswire.co.uk/news-releases/laminar-pharmaceuticals-sa-receives-recommendation-from-the-independent-data-monitoring-committee-to-advance-to-the-next-stage-of-clinglio-the-phase-2b3-clinical-trial-of-lam561-in-combination-with-rt-and-tmz-for-adults-with-n-302080711.html

en | boerse | 67917176 |